Bionano Genomics, San Diego, California.
Center for Personalized Medicine, Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, California.
J Mol Diagn. 2024 May;26(5):337-348. doi: 10.1016/j.jmoldx.2024.01.009. Epub 2024 Feb 13.
Several in silico annotation-based methods have been developed to prioritize variants in exome sequencing analysis. This study introduced a novel metric Significance Associated with Phenotypes (SAP) score, which generates a statistical score by comparing an individual's observed phenotypes against existing gene-phenotype associations. To evaluate the SAP score, a retrospective analysis was performed on 219 exomes. Among them, 82 family-based and 35 singleton exomes had at least one disease-causing variant that explained the patient's clinical features. SAP scores were calculated, and the rank of the disease-causing variant was compared with a known method, Exomiser. Using the SAP score, the known causative variant was ranked in the top 10 retained variants for 94% (77 of 82) of the family-based exomes and in first place for 73% of these cases. For singleton exomes, the SAP score analysis ranked the known pathogenic variants within the top 10 for 80% (28 of 35) of cases. The SAP score, which is independent of detected variants, demonstrates comparable performance with Exomiser, which considers both phenotype and variant-level evidence simultaneously. Among 102 cases with negative results or variants of uncertain significance, SAP score analysis revealed two cases with a potential new diagnosis based on rank. The SAP score, a phenotypic quantitative metric, can be used in conjunction with standard variant filtration and annotation to enhance variant prioritization in exome analysis.
已经开发了几种基于计算机的注释方法,用于在外显子组测序分析中对变体进行优先级排序。本研究引入了一种新的度量标准——与表型相关的显着性 (Significance Associated with Phenotypes, SAP) 评分,该评分通过比较个体的观察表型与现有的基因-表型关联来生成统计评分。为了评估 SAP 评分,对 219 个外显子组进行了回顾性分析。其中,82 个基于家族的外显子组和 35 个单体外显子组至少有一个致病变异可以解释患者的临床特征。计算了 SAP 评分,并将致病变异的排名与已知方法 Exomiser 进行了比较。使用 SAP 评分,对于 94%(82 个中的 77 个)基于家族的外显子组,已知的致病变异在排名前 10 的保留变异中排名第 10,对于其中 73%的病例排名第 1。对于单体外显子组,SAP 评分分析将已知的致病性变异排在前 10 位,占 80%(35 个中的 28 个)的病例。SAP 评分不依赖于检测到的变异,与同时考虑表型和变异级别的证据的 Exomiser 具有可比的性能。在 102 个结果为阴性或变异意义不确定的病例中,SAP 评分分析根据排名揭示了两个具有潜在新诊断的病例。SAP 评分,一种表型定量度量,可以与标准变异过滤和注释结合使用,以增强外显子组分析中的变异优先级排序。